User:Mr. Ibrahem/Niraparib

Niraparib, sold under the brand name Zejula, is a medication used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is typically used after platinum-based chemotherapy. It is taken by by mouth.

Common side effects include nausea, low platelets, tiredness, low red blood cells, constipation, abdominal pain, low white blood cells, trouble sleeping, headache, diarrhea, shortness of breath, high blood pressure, joint pain, and hot flushes. Other side effects may include myelodysplastic syndrome and infertility. Use in pregnancy may harm the baby. It is a poly ADP-ribose polymerase (PARP) inhibitor.

Niraparib was approved for medical use in the United States and Europe in 2017. In the United Kingdom 4 weeks of treatment at 200 mg per day costs the NHS about £4,500. This amount in the United States costs about 16,300 USD.